836.5500 -37.55 (-4.30%)
NSE Aug 01, 2025 15:31 PM
Volume: 1.1M
 

836.55
-4.30%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading below its 30 day SMA of 889.0
More from Strides Pharma Science Ltd.
Recommended